Our analysis confirmed the pre-identified molecular aberration used for study enrollment in 7 of 9 patients’ (78%) pre-treatment tumor biopsy samples (3 patients enrolled for PTEN loss by IHC were excluded including patients 005, 021 and 030). This evidence concerns the gene PTEN and neoplasm.